What happened
Elevance Health, Inc. (NYSE: ELV) reported third-quarter 2026 operating revenue of $50.4 billion and raised full-year 2026 guidance. It raised FY 2026 diluted EPS guidance to at least $22.00, adjusted diluted EPS guidance to at least $29.00 and operating cash flow guidance to at least $6.5 billion.
Operating revenue rose 0.7% from a year earlier. Diluted EPS was $6.27 and adjusted diluted EPS was $6.99. Quarterly operating cash flow was $1.3 billion, up $0.1 billion year over year.
Carelon operating revenue reached $19.3 billion, and Carelon operating gain rose 17% to $0.9 billion. Health Benefits operating revenue was $43.4 billion, but operating gain fell to $0.4 billion from $0.6 billion.
The benefit expense ratio was 90.6%, down 70 basis points from a year earlier. The company said stronger performance in Medicare Advantage and Individual ACA helped. It repurchased 0.8 million shares for $330 million and had about $5.0 billion of board-approved share repurchase authorization left.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| 3Q 2026 operating revenue | $50.4 billion | from $50.1 billion, +0.7% | SEC 8-K |
| 3Q 2026 diluted EPS | $6.27 | from $5.32, +17.9% | SEC 8-K |
| 3Q 2026 adjusted diluted EPS | $6.99 | from $6.03, +15.9% | SEC 8-K |
| Carelon 3Q 2026 operating revenue | $19.3 billion | from $18.3 billion, +5% | SEC 8-K |
| Benefit expense ratio | 90.6% | from 91.3%, -70 bp | SEC 8-K |
| FY 2026 operating cash flow guidance | at least $6.5 billion | SEC 8-K |
Read more: Elevance Health (ELV) stock analysis and investment case
Why it matters
OptimistFi's case is that Elevance turns scale into underwriting earnings only if it keeps medical costs in check and converts earnings into cash. This filing helps that case on cash flow, because the company raised FY 2026 operating cash flow guidance to at least $6.5 billion. It also shows a split in the business, with Carelon improving and Health Benefits weakening.
Operating revenue increased by $353 million from the prior-year quarter, but operating gain was unchanged at $1.3 billion. The adjusted operating expense ratio rose 90 basis points to 11.3%, which limits the margin story. The main concern is that Health Benefits operating gain fell to $0.4 billion from $0.6 billion, even with the lower benefit expense ratio.
Stock perps: every US stock that trades as a perpetual future, by leverage, live
What's next
The conference call was set for today at 8:30 a.m. EDT. The fourth quarter 2026 dividend is payable on December 18, 2026 to shareholders of record at the close of business on December 4, 2026. The replay will be available until the end of the day on November 20, 2026.
Investors will look for signs that the higher guidance comes with better margins and steady cash flow. More margin recovery would strengthen the case. Another flat operating-gain quarter would weaken it.
More from OptimistFi
- ELV stock: the Elevance Health thesis, its status and the next test to watch
- Stock research on every company OptimistFi covers
From OptimistFi Perps
- Open interest live: crypto and stock perps by exchange
- All perp markets: price, open interest and funding by venue
- Futures calculator: liquidation price, PnL and fees by exchange
- Perp funding rates live: what longs and shorts pay on every venue
- Stock perps vs tokenized stocks: how US shares trade around the clock
Sources
- SEC 8-K earnings release — Third-quarter 2026 earnings release and updated guidance.
- Form 8-K — Current report filed October 21, 2026.
Read the full OptimistFi thesis on Elevance Health, Inc.: https://optimistfi.com/stocks/ELV
See what would break the Elevance Health, Inc. thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full Elevance Health, Inc. investment case, its status and the next test to watch live on the Elevance Health, Inc. thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
